Home › Trial NCT05524935
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
- Trial IDNCT05524935
- StatusActive Not Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorH. Lee Moffitt Cancer Center and Research Institute
- Enrollment12
- Start date2022-10-11
- ConditionsUveal Melanoma · Ocular Melanoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.